Provided is a prodrug of levodopa, namely (2S)-2-amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, salts thereof, particularly the hydrochloride and tosylate salts, and crystalline forms thereof. Further provided is a pharmaceutical composition comprising the prodrug and medicaments comprising the prodrug. The compound is useful in the treatment of Parkinson&rsquo；s disease/syndrome.
